...
首页> 外文期刊>Infectious Agents and Cancer >Co-existence of hepatocellular carcinoma and cystic echinococcosis
【24h】

Co-existence of hepatocellular carcinoma and cystic echinococcosis

机译:肝细胞癌和囊性超声阴性的共存

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Co-existence of hepatocellular carcinoma (HCC) and cystic echinococcus (CE) is extremely rare. Echinococcus granulosus may exhibit a protective effect against cancer. Herein, this study aimed to evaluate the possible effects of echinococcal infection on HCC patients. Three thousand three hundred hepatic CE patients and 815 HCC patients were retrospectively reviewed between January 2010 and December 2018 in Xinjiang, China, and these patients were 1:5 matched according to their sex, age and tumor TMN stage, and only 13 patients coexisted both CE and HCC. Preoperative ultrasonography (US), computed tomography (CT), liver magnetic resonance imaging (MRI) and dot immune-gold filtration assay (DIGFA) were used for preoperative identification and intraoperative specimens from liver resections were pathologically examined for further confirmation. Survival time was analyzed through Cox proportional hazard model analysis. The co-existing incidence rate of two diseases was 0.39%. For these concurrent cases, HCC was all at the advanced stage and CE lesions were inactive. Median survival time for HCC patients was 6?month (1–17). However, it was 8?month (3–90) for the co-existing cases and was much longer than the median survival time of HCC patients (P0.05), which was closely associated with tumor size, location, TMN stage and hydatid size, location, classification. Four of the patients underwent surgical intervention and their median survival time was 17?month (3–68). Echinococcus granulosus may elicit a protective effect against the development and progression of HCC, while more basic and clinical researches are needed.
机译:肝细胞癌(HCC)和囊性超声波能(CE)的共存极罕见。 Echinococcus颗粒可能对癌症表现出保护作用。在此,本研究旨在评估echInococal感染对HCC患者的可能影响。 2010年1月和2018年12月在新疆1月至2018年12月期间回顾性审查了三千三百肝CE患者,这些患者根据其性别,年龄和肿瘤TMN阶段匹配,只有13名患者共存CE和HCC。术前超声检查(US),计算断层扫描(CT),肝磁共振成像(MRI)和点免疫金过滤测定(DIGFA)用于术前鉴定和来自肝切除的术中标本进行病理检查,以进一步确认。通过Cox比例危险模型分析分析生存时间。两种疾病的共存发病率为0.39%。对于这些并发病例,HCC全部位于晚期阶段,CE病变处于非活动状态。 HCC患者的中位生存时间为6?月(1-17)。但是,它为共存病例为8?月份(3-90),比HCC患者的中位生存时间(P <0.05),与肿瘤大小,位置,TMN阶段和包发虫密切相关大小,位置,分类。四名患者接受手术干预的患者及其中位生存时间为17?月(3-68)。 echinococcus颗粒可能会引起对HCC的开发和进展的保护作用,而需要更多的基本和临床研究。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号